Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from a two-and-a-half-year interim analysis from the ongoing Phase ...
Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
Eight participants achieved HBsAg loss at any time.Two participants met criteria for functional cure. Two participants who ...
GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024
Ipsen to present new data on elafibranor at The Liver Meeting® 2024Launch of Iqirvo® (elafibranor)1 on track with ...
News Medical on MSN7d
Mouse models for the study of liver fibrosis regression in vivo and ex vivo
This review discussed experimental mouse models used in the pre-clinical study of liver fibrosis regression, a pivotal ...
Nasdaq1mon
Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease
This was observed rapidly and maintained over the period of the study ... rare cholestatic liver disease portfolio. Kayfanda is known in ALGS as Bylvay® outside of the European Union (E.U ...